Quick Answer
Design Therapeutics, Inc. reported Earnings Per Share Diluted of $1.22 (loss) per share for the year ending 2025.
- Design Therapeutics, Inc. showed a decrease of -38.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Design Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.14 (loss) per share | Q3 2021: $0.21 (loss) per share | Q1 2022: $0.24 (loss) per share | Q2 2022: $0.27 (loss) per share | Q3 2022: $0.32 (loss) per share | Q1 2023: $0.35 (loss) per share | Q2 2023: $0.36 (loss) per share | Q3 2023: $0.28 (loss) per share | Q1 2024: $0.20 (loss) per share | Q2 2024: $0.21 (loss) per share | Q3 2024: $0.23 (loss) per share | Q1 2025: $0.31 (loss) per share | Q2 2025: $0.34 (loss) per share | Q3 2025: $0.30 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Design Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 58.4%.
- Historical annual values: Fiscal year 2025: $1.22 (loss) per share | Fiscal year 2024: $0.88 (loss) per share | Fiscal year 2023: $1.19 (loss) per share | Fiscal year 2022: $1.14 (loss) per share | Fiscal year 2021: $0.77 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: